Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oncogene expression in cervical cancer

V V Baker1

  • 1Dept. of Obstetrics, Gynecology & Reproductive Science, UT-Health Science Center at Houston, Texas 77030.

Cancer Treatment and Research
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithelial ovarian cancer cells.

Gynecologic oncology·2003
Same author

[Synergistic efficacy of adenovirus-mediated bcl-Xs gene therapy and cisplatin in ovarian cancer cell].

Zhonghua fu chan ke za zhi·2002
Same author

Treatment options for ovarian cancer.

Clinical obstetrics and gynecology·2001
Same author

A bcl-x(S) adenovirus demonstrates therapeutic efficacy in an ascites model of human breast cancer.

Journal of the Society for Gynecologic Investigation·2000
Same author

Expression of HOXD10 gene in normal endometrium and endometrial adenocarcinoma.

Journal of the Society for Gynecologic Investigation·1998
Same author

Transforming growth factor-alpha and insulin-like growth factor-I, but not epidermal growth factor, elicit autocrine stimulation of mitogenesis in endometrial cancer cell lines.

Gynecologic oncology·1998
Same journal

Clinical Trials and Translational Advances in Metabolic Targeting.

Cancer treatment and research·2026
Same journal

Tools and Technologies for Studying Cancer Metabolism.

Cancer treatment and research·2026
Same journal

Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.

Cancer treatment and research·2026
Same journal

Biomarkers of Cancer Metabolism and Therapeutic Response.

Cancer treatment and research·2026
Same journal

Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.

Cancer treatment and research·2026
Same journal

Metabolic Reprogramming in Cancer Stem Cells.

Cancer treatment and research·2026
See all related articles

Molecular insights into cervical dysplasia and neoplasia are advancing, yet clinical applications in diagnosis and treatment lag. Further research into genetic alterations and oncogene mutations is crucial for improved patient outcomes.

Area of Science:

  • Molecular oncology
  • Cervical cancer research

Background:

  • Significant progress in understanding the molecular basis of cervical dysplasia and neoplasia.
  • Current diagnostic and therapeutic strategies have not yet benefited from these molecular advancements.
  • Variability in reported genetic alterations may stem from analytical methods, tissue fixation, and sample size.

Purpose of the Study:

  • To review the current understanding of molecular alterations in cervical neoplasia.
  • To identify key genetic changes involved in tumor initiation and progression.
  • To explore the potential clinical applications of these findings, particularly oncogene mutations.

Main Methods:

  • Review of published literature on molecular alterations in cervical dysplasia and neoplasia.
  • Analysis of genetic alterations in preneoplastic and early-stage cervical neoplasms.

Related Experiment Videos

  • Investigation into the prognostic value of oncogene mutations.

    • Main Results:

    • Several genetic alterations are consistently observed in preneoplastic and early-stage cervical neoplasms.
    • The precise role of specific genetic alterations in tumor initiation requires further elucidation.
    • Oncogene mutations show promise for prognostic applications, pending larger patient cohort studies.

    Conclusions:

    • While molecular understanding has advanced, clinical translation for cervical cancer diagnosis and treatment is pending.
    • Further research is essential to determine which genetic alterations drive tumor initiation.
    • Standardized methods for tissue fixation, antibody development, and quantitative analysis are critical for future progress.